← Back to Search

Adderall XR + TMS for Depression (Stimulant-rTMS Trial)

Phase < 1
Waitlist Available
Led By Scott Wilke, MD
Research Sponsored by University of California, Los Angeles
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
All subjects will be between the ages of 18-65 and will meet DSM-V criteria for a current episode of major depressive disorder.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 weeks- 6 assessments from baseline to study completion
Awards & highlights

Stimulant-rTMS Trial Summary

This trial looks at the effects of Adderall XR on subjects receiving brain stimulation therapy for Major Depressive Disorder. Subjects will be randomly assigned to an active or placebo group.

Who is the study for?
This trial is for adults aged 18-65 with Major Depressive Disorder who haven't improved after two different antidepressant treatments. They can be on other psychotropic meds, but not psychostimulants or benzodiazepines. Participants must not have certain mental health conditions, substance misuse history, severe physical health issues like heart disease, glaucoma, hyperthyroidism, or metal in the head.Check my eligibility
What is being tested?
The study tests if Adderall XR (a stimulant medication) helps brain stimulation therapy work better for depression. Half of the participants will get Adderall and half a placebo pill that does nothing. Everyone gets the same brain stimulation treatment over seven visits including mood assessments.See study design
What are the potential side effects?
Adderall XR may cause nervousness, restlessness, headache, dizziness, fearfulness or anxiety; it might also increase blood pressure and heart rate. The side effects vary from person to person.

Stimulant-rTMS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 65 years old and have been diagnosed with major depression.

Stimulant-rTMS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 weeks- 6 assessments from baseline to study completion
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 weeks- 6 assessments from baseline to study completion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean Percent Change in Self-rated Inventory of Depressive Symptoms

Stimulant-rTMS Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: ActiveActive Control1 Intervention
Subjects randomized to Adderall will take an tablet/capsule by mouth daily.
Group II: PlaceboPlacebo Group1 Intervention
Subjects randomized to placebo will take an identical-appearing tablet/capsule and, in order to maintain blinding, will also take one tablet by mouth daily. The placebo substance will be sugar.

Find a Location

Who is running the clinical trial?

University of California, Los AngelesLead Sponsor
1,528 Previous Clinical Trials
10,276,821 Total Patients Enrolled
101 Trials studying Depression
48,413 Patients Enrolled for Depression
Scott Wilke, MDPrincipal InvestigatorUCLA Semel

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
Scott A. Wilke, MD 2021. "Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04509102.
All > Mdd
~10 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top